相关实验视频

Updated: Jun 14, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

在非小细胞肺癌中的KRAS^G12C抑制剂:一篇评论

Min Tang^1,2, Yijun Wu^1,2, Xiufeng Bai^3,4

¹Division of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

OncoTargets and therapy

|August 29, 2024

概括

针对非小细胞肺癌 (NSCLC) 中的KRAS G12C突变显示出希望,特别是在大脑转移方面. 本综述涵盖了当前的KRAS G12C疗法,它们的局限性以及NSCLC患者的未来方向.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

鼠肉瘤病毒 (RAS) GTPase突变是非小细胞肺癌 (NSCLC) 的关键驱动因素.
基尔斯顿大鼠肉瘤病毒瘤基因同源 (KRAS) 是NSCLC中最常发生突变的RAS异型.
从历史上看,KRAS突变,特别是G12C,被认为是无法治疗的目标.

研究的目的:

审查针对NSCLC中KRAS G12C突变的治疗方法的进展.
讨论当前KRAS G12C抑制剂治疗的挑战和局限性.
探索在KRAS p.G12C突变NSCLC患者中管理大脑转移的未来前景.

主要方法:

临床前和临床研究的文献综述.
针对KRAS G12C的治疗策略的分析.
专注于与NSCLC中大脑转移相关的结果.

主要成果:

开发特定的KRAS G12C抑制剂已成为突破性的治疗方法.
目前的疗法显示出有效性,但在克服抗性和治疗特定并发症 (如大脑转移) 方面存在局限性.
需要进一步的研究来优化治疗策略和改善患者的治疗结果.

结论:

克拉斯G12C抑制剂代表了NSCLC治疗的重大进展.
解决治疗的局限性,特别是大脑转移,对于改善生存至关重要.
未来的研究应该专注于针对KRAS突变NSCLC的新型治疗方法和组合策略.

关键词:

在G12C中,G12C是指G12C.克拉斯 (Kras) 是一个国家.大脑转移是大脑转移.非小细胞肺癌的肺癌.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...